This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What does the future of heartdisease detection look like? EchoSolv, the groundbreaking AI platform developed by Echo IQ, is revolutionizing the detection of aortic stenosis. EchoSolv, the groundbreaking AI platform developed by Echo IQ, is revolutionizing the detection of aortic stenosis.
Background Infants with congenital heartdisease (CHD) are clinically vulnerable to cardiac deteriorations and intercurrent infections. We aimed to quantify the impact of health system disruptions during the COVID-19 pandemic, on their clinical outcomes and whether these differed by socioeconomic and ethnic subgroups.
Valvular heartdisease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aortic valve replacement (TAVR).
Objective This study aims to assess the ability of state-of-the-art machine learning algorithms to detect valvular heartdisease (VHD) from digital heart sound recordings in a general population that includes asymptomatic cases and intermediate stages of disease progression.
Video Pitfalls in Adult Congenital HeartDisease for the Aortic Surgeon kchalko Sun, 12/01/2024 - 13:53 STS President Dr. Jennifer Romano presented at the 2024 STS and Asian Society for Cardiovascular and Thoracic Surgery Aortic Summit in Tokyo (November 16, 2024) on adults with congenital heartdisease.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
A review in The Lancet finds that 20% of the world population carries a genetic risk factor for cardiovascular diseases such as heart attacks, strokes, and aortic valve stenosis: Increased levels of a lipid particle called lipoprotein(a). It is the most common genetic cause of cardiovascular diseases.
Abstract Worldwide, valvular heartdisease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock.
Valvular heartdisease is a common cause of morbidity and mortality worldwide and has no effective medical therapy. Severe disease is managed with valve replacement procedures, which entail high health care–related costs and postprocedural morbidity and mortality. Circulation, Ahead of Print.
Valvular heartdisease (VHD) has been a significant health problem, particularly in developed countries, in relation to the aging population. Recent developments in the management of VHD require a more accurate assessment of disease severity to determine the need for transcatheter interventions or open heart surgery.
IntroductionVentricular septal defect (VSD) is a common congenital heartdisease (CHD), accounting for 2030% of all CHD cases. ResultsThe procedure achieved a success rate of 96.4%, with three failures due to large defects near the aortic valve causing significant aortic regurgitation or residual shunting.
Large and rare duplications and deletions in a chromosome region known as 22q11.2 , which involves genes that regulate cardiac development, are linked to nonsyndromic bicuspid aortic valve disease.
6, 2025 Medtronic plc hasannounced it received CE ( Conformit Europenne ) Mark for the Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heartdisease patients with native or surgically repaired right ventricular outflow tract (RVOT). Eur J Heart Fail.
Anomalous aortic origin of the coronary artery (AAOCA) is a rare congenital heartdisease. Therefore, optimal indications for surgery in patients with severe aortic valve stenosis (AS) complicated by AAOCA rem.
Aortic dissection in pediatrics is an extremely rare condition, which is generally related to predisposing factors such as connective tissue disorders, congenital heartdisease and systemic arterial hypertensi.
The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first transcatheter aortic valve replacement (TAVR) in 2002, as well as the first transcatheter mitral commissurotomy in 1995 and the first balloon aortic valvuloplasty in 1986. He passed away Feb. 16, 2024 at the age of 79.
A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heart valve disease -- aortic stenosis (AS).
Fetal aortic valvuloplasty is considered for fetuses with severe valvar aortic stenosis and echocardiographic features suggesting a risk of progression to hypoplastic left heart syndrome. Though surgical options are available for infants with hypoplastic left heart syndrome, morbidity and mortality are high.
Abnormal blood flow in the aorta is linked to inflammation and breakdown of the vessel wall in conditions where the aorta is dilated. The findings can contribute to better diagnosis and open up new ways to assess the risk of serious and usually fatal complications, such as rupture of the aorta.
Recently published research shows a medical device may be beneficial for patients who have previously had a stroke and are planning to undergo a transcatheter aortic valve replacement, a type of heart valve operation.
Background: Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. The patient cohort had mean age of 7711 years, was 47% female, and had mean aortic valve area 0.80.1
Medtronic is proud to support the incoming cohort of dynamic structural heartdisease specialists to the CTR REACH program,” said Jeffrey Popma , M.D., vice president and chief medical officer for the Coronary & Renal Denervation business and the Structural Heart & Aortic business at Medtronic.
The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.
Pathogeneses include connective tissue disorders, smooth muscle contraction disorders, and congenital heartdisease, including bicuspid aortic valve, among others. The American Heart Association has published guidelines for diagnosis and management of thoracic aorticdisease.
Journal of the American Heart Association, Volume 13, Issue 24 , December 17, 2024. BackgroundValvular heartdisease poses an escalating global health challenge with an increasing impact on mortality and disability. cases of rheumatic heartdisease, 13.3 In 2021, an estimated 54.8 million (95% UI, 11.415.2)
Attendees can join with their peers and participate in sessions on structural heartdisease, congenital heartdisease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronary artery disease, vascular heartdisease, debates and games and early career topics.
Objectives Assessment of frailty prior to aortic valve intervention is recommended in European and North American valvular heartdisease guidelines. These data would support its use in the preoperative assessment of elderly patients undergoing aortic valve interventions.
A 76-year-old woman with a history of double valve replacement (Aortic and mitral valves) for rheumatic heartdisease, presented with acute dyspnea after a switch from Warfarin to LMWH before a planned bone marrow biopsy. Hence distal protection by an Aortic sentinel device or its equivalent (FilterWire EZ, Tri-guard) is a must.
SAVR after TAVR Surgical aortic valve replacement after prior TAVR is the fastest-growing cardiac surgery procedure in the U.S. The STS rolled out all three interactive, mobile-friendly risk calculators in April 2024, adding to its existing portfolio of risk calculators for adult cardiac surgery.
We know that structural heartdisease and heart failure are the leading causes of hospitalization and morbidity in the U.S. This milestone makes AISAP the first company in the world to secure FDA clearance in the CADx pathway for the comprehensive diagnosis of structural heartdiseases using POCUS.
Odds ratio [OR] is as follows: 1.992, 95% confidence interval [CI]: 0.9831.007, p=0.266, aortic clamp time per minutes: OR: 1.008, 95% CI: (0.9971.019), p=0.164, HLM time per minutes: OR: 0.996, 95% CI: (0.9911.001), p=0.146, Operation time per minutes: OR: 1.000, 95% CI: (0.9951.004), p=0.861.ConclusionThe
Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heartdisease in Europe. Abstract Aims Tricuspid regurgitation (TR) is commonly observed in patients with severe left-sided valvular heartdisease (VHD).
In these panel discussions, host Andrea Price, MS, AACC brings together Marian Hawkey, RN and Misty Theriot, BSN to explore best practices related to structural heartdisease.
Over the last two decades, the differentiation of severe from non-severe aortic valve stenosis with echocardiography has become more complex. Low flow can result in low gradient and, thereby, mask severe aortic stenosis. The consideration of flow is now frequently essential to evaluate haemodynamic stenosis severity.
The large aortic regurgitation jet can be seen as a mosaic jet in the left ventricular outflow tract anterior to the anterior mitral leaflet. A portion of the thickened aortic valve can be seen between the aorta and left ventricle. Thickening of both aortic and mitral leaflets indicate the possible etiology as rheumatic.
Cardiac Surgery after Transcatheter Aortic Valve Replacement: Trends and Outcomes The researchers set out to document trends and outcomes in cardiac surgery following transcatheter aortic valve replacement (TAVR), a topic gaining importance as reports of subsequent cardiac operations and early TAVR explantations increase.
Lipoprotein(a) (Lp[a]) can improve the accuracy of assessment of atherosclerotic cardiovascular disease and the risk of aortic valve stenosis. Currently, there is no specific treatment to lower its circulating concentration. Raised Lp(a) is a feature of familial hypercholesterolaemia.
BACKGROUND:Bioprosthetic valve dysfunction and reoperations/reinterventions are common after aortic valve replacement (AVR) with bioprosthetic valves, leading to cycles of left ventricular (LV) pressure overload and unloading. METHODS:Retrospective study of adults with congenital heartdisease who underwent AVR at Mayo Clinic (20032023).
Atrial septal defect (ASD) is a common congenital heartdisease, and currently, transcatheter intervention is the most common clinical treatment method. However, certain complications still occur during the pe.
24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content